Treatment of Fibrous Dysplasia of Bone in Females with Gonadotropin-Independent Precocious Puberty and Frequent Vaginal Bleeding

This clinical scenario involves fibrous dysplasia of bone in female patients where the condition drives gonadotropin-independent sex steroid production, leading to precocious puberty, advanced bone age, and recurrent vaginal bleeding — findings that together signal the need for hormonal intervention.

Gonadotropin-independent sex steroid production in this setting results in early sexual development and recurrent ovarian cysts. Treatment is indicated specifically when bone age is advanced and frequent bleeding episodes are present.

Management targets estrogen-pathway modulation. The structured protocol includes a sequence of hormonal agents — with options for second-line use or adjuvant combination when the initial approach is insufficient. The full treatment algorithm, including sequencing and agent selection, is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Treatment for precocious puberty is indicated if bone age is advanced and there is frequent bleeding.

Gonadotropin-independent sex steroid production resulting in precocious puberty, recurrent ovarian cysts in girls and women or autonomous testosterone production in boys and men.

First line therapy is letrozole, with tamoxifen or fulvestrant as second line or adjuvants.

DOI: 10.1186/s13023-019-1102-9

View source ↗